Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
04 mars 2023 10h30 HE
|
Esperion Therapeutics, Inc.
– NEXLETOL Significantly Reduced Risk of Major Adverse Cardiovascular Events (MACE-4) and (MACE-3) by 13% (P=0.004) and 15% (P=0.006), Respectively, and Significantly Reduced Risk of Myocardial...
Esperion Launches New Scientific Website
24 févr. 2023 13h40 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 24, 2023 (GLOBE NEWSWIRE) -- With a focus on science and clinical evidence, Esperion today announced the launch of the website, esperionscience.com. This website, geared...
Esperion to Participate in the Cowen 43rd Annual Healthcare Conference
23 févr. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Sheldon Koenig, president and chief executive officer, will present at Cowen’s 43rd annual Health...
CLEAR Outcomes Company Update Call: Detailed Results Discussion
22 févr. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a conference call and webcast on Monday, March 6th, 2023 where Esperion Chief Medical Officer...
Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
21 févr. 2023 07h00 HE
|
Esperion Therapeutics, Inc.
– Landmark CLEAR Outcomes Trial Successfully Completed and Met the Major Adverse Cardiovascular Events (MACE-4) Primary Endpoint and Additional Key Secondary Endpoints; Additional Details in 11 Days...
Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC
20 févr. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announces that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial will...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
13 févr. 2023 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 13, 2023, the Compensation Committee of Esperion’s Board of Directors granted six new...
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
07 févr. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2022 financial results before the open of the U.S. financial...
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
11 janv. 2023 11h00 HE
|
Esperion Therapeutics, Inc.
CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement...
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
08 janv. 2023 19h00 HE
|
Esperion Therapeutics, Inc.
– Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive...